Synairgen PLC (AIM:SNG, OTC:SYGGF) said its further analysis of data from its phase III SPRINTER trial of its lead asset, SNG001, will be showcased at a leading industry conference.
It has been selected for two sessions at the ATS 2022 International Conference: The clinical trials symposium on May 16 and a thematic poster session entitled Expanding Our Insight Into COVID-19 a day later.
“The selection of SNG001 into the clinical trials symposium session follows a pre-evaluation of key results by an International Conference Committee,” Synairgen told investors.
“The session is a platform for important trial results that are novel and represent important new understanding.”
SNG001 is an investigational formulation for inhalation containing the broad-spectrum antiviral protein, interferon beta, that was most recently assessed for potential use in Covid sufferers.
While the SPRINTER trial did not hit its end goals, the data pointed to an "encouraging trend" toward preventing severe disease and death associated with coronavirus.